Defining Strategies for Improving Endothelial and Fibrinolytic Dysfunction in Obesity

• Status: Terminated
• Trial end date: 2011-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The combination of high blood pressure and having central obesity is an increasing important factor for heart disease in men and women. It can also lead to the early development of hardening of the arteries and increased risk of a stroke. This study will analyze patients' genetic make up to identify who may be at greater risk for heart disease and strokes in relationship to high blood pressure and central obesity.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Vanderbilt University; Vanderbilt University Medical Center
• Treatments: Eplerenone; Ramipril

Criteria

Inclusion Criteria:

• Male or females between the ages of 18 to 65 years of age.

• Documented diagnosis for the metabolic syndrome:

• Subjects with hypertension (SP>130mmHg)

• Subjects with central obesity (females waist >35"; males waist >40")

• Subjects with dyslipidemia (HDL <40mg/dl, triglycerides > 150 mg/dl)

• Subjects who are insulin resistance (fasting glucose >100mg/dl)

Exclusion Criteria:

• Subjects who smoke

• Women who are pregnant (confirmed by urine beta-HCG).

• Women who are breast feeding

• Subjects with documentation of the following health risk:

• Subjects with serum creatinine >2.0 mg/dl (males), >1.8 mg/dl (females)

• Subjects whose creatinine clearance < 50 mls/min

• Subjects with serum potassium >5.5mEql

• Subjects with Type 2 diabetes with microalbuminuria (spot urine protein/creatinine ration >0.2)

• Subjects who are currently taking the following medications:

• Warfarin